(E)-3-(4-hydroxyphenyl)-1-pyridin-4-ylprop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(4-hydroxyphenyl)-1-pyridin-4-ylprop-2-en-1-one
• 化学式: C₁₄H₁₁NO₂
• 分子量: 225.24
• InChiKey: NTBHFVAUTUKRMT-ZZXKWVIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-hydroxyphenyl)-1-pyridin-4-ylprop-2-en-1-one 、 2-氯-N,N-二甲基乙胺 、 柠檬酸 以38%的产率得到
  参考文献：
  名称：

  BRADLEROVA, A.;DURINDA, J.;MISIKOVA, E., CHEM. ZVESTI, 1983, 37, N 2, 251-252

  摘要：

  DOI：
• 作为产物：
  描述：

  对羟基苯甲醛 在 4-甲基苯磺酸吡啶 、 对甲苯磺酸 、 potassium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 5.08h， 生成 (E)-3-(4-hydroxyphenyl)-1-pyridin-4-ylprop-2-en-1-one
  参考文献：
  名称：

  [EN] ESTROGENIC COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS ŒSTROGÉNIQUES ET MÉTHODES D'UTILISATION

  摘要：

  Estrogenic compounds, compositions and method are presented. The novel estrogenic compounds comprise novel chalcone derivatives and analogs that have little or no measurable estrogen (estradiol, E2) activity but potentiate E2 activity without binding an estrogen receptor (ER). The novel compositions comprise one or more of the novel estrogenic compounds, and may optionally comprise one or more excipients. The one or more excipients may be pharmaceutically acceptable. The one or more excipients may comprise at least one compound that does not occur in nature with estrogenic compounds. The method comprises administering a pharmaceutical composition comprising an estrogenic compound described herein to a patient in need of treatment with an estrogenic compound or pharmaceutical composition.

  公开号：

  WO2024026034A1

文献信息

• BRADLEROVA, A.;DURINDA, J.;MISIKOVA, E., CHEM. ZVESTI, 1983, 37, N 2, 251-252
  作者：BRADLEROVA, A.、DURINDA, J.、MISIKOVA, E.

  DOI：——

  日期：——
• [EN] ESTROGENIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ŒSTROGÉNIQUES ET MÉTHODES D'UTILISATION
  申请人：[en]IATERION, INC.

  公开号：WO2024026034A1

  公开（公告）日：2024-02-01

  Estrogenic compounds, compositions and method are presented. The novel estrogenic compounds comprise novel chalcone derivatives and analogs that have little or no measurable estrogen (estradiol, E2) activity but potentiate E2 activity without binding an estrogen receptor (ER). The novel compositions comprise one or more of the novel estrogenic compounds, and may optionally comprise one or more excipients. The one or more excipients may be pharmaceutically acceptable. The one or more excipients may comprise at least one compound that does not occur in nature with estrogenic compounds. The method comprises administering a pharmaceutical composition comprising an estrogenic compound described herein to a patient in need of treatment with an estrogenic compound or pharmaceutical composition.